A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal.

CONCLUSIONS: Sigurgeirsson et al. conclude that the long-term management of mild-to-moderate AD in children with both TCS and PIM is safe, and that PIM has similar efficacy to TCS. Further, they conclude that their data support the use of PIM as a first-line treatment of mild-to-moderate AD in children. PMID: 28868633 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28868633?dopt=Abstract

Source: The British Journal of Dermatology - September 4, 2017 Category: Dermatology Authors: Weidinger S, Baurecht H, Schmitt J Tags: Br J Dermatol Source Type: research